Core Viewpoint - The Trade Desk (TTD) is expected to report a year-over-year decline in earnings despite higher revenues, with the market closely watching how actual results compare to estimates [1][2]. Company Summary - The Trade Desk is anticipated to post quarterly earnings of $0.25 per share, reflecting a year-over-year decrease of 3.9%. Revenues are projected to reach $574.27 million, which is an increase of 16.9% from the same quarter last year [3]. - The consensus EPS estimate has been revised down by 6.87% over the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4][10]. - The Most Accurate Estimate for The Trade Desk is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -9.45%. The stock currently holds a Zacks Rank of 5, making it challenging to predict an earnings beat [11][10]. Earnings Surprise History - In the last reported quarter, The Trade Desk was expected to post earnings of $0.58 per share but actually delivered $0.59, resulting in a surprise of +1.72%. Over the past four quarters, the company has beaten consensus EPS estimates four times [12][13]. Industry Context - Another player in the Zacks Internet - Services industry, Uber Technologies (UBER), is expected to report earnings of $0.51 per share for the same quarter, indicating a significant year-over-year increase of 259.4%. Revenues are expected to be $11.6 billion, up 14.5% from the previous year [17]. - The consensus EPS estimate for Uber has been revised down by 1.4% over the last 30 days, and it currently has an Earnings ESP of -0.20%, combined with a Zacks Rank of 3, making it difficult to predict an earnings beat [18].

Company Overview - CG Oncology, Inc. (CGON) is expected to report flat earnings compared to the previous year, with a projected quarterly loss of $0.36 per share, indicating no change from the year-ago quarter [3][10] - Revenues are anticipated to be $0.6 million, reflecting a 13.2% increase from the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4] - The Zacks Earnings ESP for CG Oncology is -21.30%, suggesting a bearish sentiment among analysts regarding the company's earnings prospects [10][11] Historical Performance - In the last reported quarter, CG Oncology was expected to post a loss of $0.41 per share but actually reported a loss of $0.48, resulting in a surprise of -17.07% [12] - Over the past four quarters, the company has beaten consensus EPS estimates two times [13] Comparison with Industry Peers - Stoke Therapeutics, Inc. (STOK), another player in the Zacks Medical - Biomedical and Genetics industry, is expected to post a loss of $0.37 per share, which represents a year-over-year change of +35.1% [17] - Stoke Therapeutics has an Earnings ESP of 32.43% and a Zacks Rank of 2 (Buy), indicating a higher likelihood of beating the consensus EPS estimate [18]

Company Overview - Wolverine World Wide (WWW) is anticipated to report a year-over-year increase in earnings, with a projected earnings per share (EPS) of $0.16, reflecting a significant increase of +220% compared to the previous year [3] - The expected revenue for the quarter is $395.35 million, which represents a slight increase of 0.1% from the same quarter last year [3] Earnings Expectations - The earnings report is scheduled for release on May 8, 2025, and could influence the stock price depending on whether the actual results exceed or fall short of expectations [2] - The consensus EPS estimate has been revised down by 6.54% over the last 30 days, indicating a more cautious outlook from analysts [4] Earnings Surprise Prediction - The Zacks Earnings ESP (Expected Surprise Prediction) model indicates that the Most Accurate Estimate for Wolverine is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -17.46% [10][11] - This negative Earnings ESP, combined with a Zacks Rank of 5 (Strong Sell), suggests a challenging environment for predicting an earnings beat [11] Historical Performance - In the last reported quarter, Wolverine exceeded the consensus EPS estimate by delivering earnings of $0.42 per share against an expectation of $0.41, resulting in a surprise of +2.44% [12] - Over the past four quarters, the company has beaten consensus EPS estimates three times, indicating some level of reliability in its earnings performance [13] Industry Comparison - In the broader context of the Zacks Shoes and Retail Apparel industry, Steven Madden (SHOO) is expected to report earnings of $0.46 per share, reflecting a year-over-year decline of -29.2% [17] - Steven Madden's revenue is projected to be $561.97 million, which is an increase of 1.7% from the previous year [17] - Despite a recent downward revision of 6.6% in the consensus EPS estimate for Steven Madden, it has a positive Earnings ESP of 9.29%, although it carries a Zacks Rank of 4 (Sell), complicating predictions for an earnings beat [18]

Core Viewpoint - Clear Secure (YOU) is expected to report a year-over-year increase in earnings and revenues for the quarter ended March 2025, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - The upcoming earnings report is anticipated to be released on May 8, 2025, with expected earnings of $0.30 per share, reflecting a +7.1% change year-over-year, and revenues projected at $208.17 million, up 16.3% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 7.41% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Clear Secure is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +7.86% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [8]. - Clear Secure currently holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Clear Secure exceeded the expected earnings of $0.28 per share by delivering $0.90, resulting in a surprise of +221.43% [12]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [13]. Conclusion - Clear Secure is positioned as a compelling candidate for an earnings beat, but investors should consider other factors influencing stock performance beyond just earnings results [16].

Core Viewpoint - Akebia Therapeutics (AKBA) is anticipated to report a year-over-year increase in earnings driven by higher revenues in its upcoming earnings report for the quarter ended March 2025, with a consensus outlook suggesting a quarterly loss of $0.03 per share, reflecting a 66.7% improvement from the previous year, and revenues expected to reach $45.21 million, a 38.6% increase from the same quarter last year [1][3]. Earnings Expectations - The stock price may rise if the actual earnings exceed expectations in the upcoming report, while a miss could lead to a decline in stock value [2]. - The consensus EPS estimate has been revised 30% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates a positive Earnings ESP of +45.46% for Akebia Therapeutics, suggesting a strong likelihood of beating the consensus EPS estimate [11]. - The company currently holds a Zacks Rank of 3, which, when combined with the positive Earnings ESP, indicates a favorable outlook for the upcoming earnings report [11]. Historical Performance - In the last reported quarter, Akebia Therapeutics was expected to post a loss of $0.08 per share but actually reported a loss of $0.10, resulting in a surprise of -25% [12]. - Over the past four quarters, the company has only surpassed consensus EPS estimates once [13]. Industry Comparison - Another player in the Zacks Medical - Drugs industry, Heron Therapeutics (HRTX), is expected to report a loss of $0.01 per share for the same quarter, reflecting a year-over-year change of +50%, with revenues projected at $37.08 million, a 7% increase from the previous year [17]. - Heron Therapeutics has seen a 50% upward revision in its consensus EPS estimate over the last 30 days and holds an Earnings ESP of 100.00%, indicating a strong likelihood of beating the consensus EPS estimate [18].

Core Viewpoint - The market anticipates a year-over-year decline in earnings for Altice USA, Inc. (ATUS) due to lower revenues, with a consensus estimate of a quarterly loss of $0.09 per share and revenues of $2.16 billion, reflecting a 3.9% decrease from the previous year [1][3]. Earnings Expectations - The upcoming earnings report is expected to be released on May 8, and the stock may rise if the actual results exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised down by 7.14% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Altice USA is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +11.11% [10][11]. - However, the stock holds a Zacks Rank of 5, which complicates the prediction of an earnings beat [11]. Historical Performance - In the last reported quarter, Altice USA was expected to post earnings of $0.03 per share but instead reported a loss of $0.12, resulting in a surprise of -500% [12]. - The company has not beaten consensus EPS estimates in any of the last four quarters [13]. Conclusion - While Altice USA does not appear to be a strong candidate for an earnings beat, investors should consider other factors when making decisions regarding the stock ahead of the earnings release [16].

Core Viewpoint - The market anticipates a year-over-year decline in Allbirds, Inc. (BIRD) earnings due to lower revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - Allbirds is expected to report a quarterly loss of $3.85 per share, reflecting a -6.9% change year-over-year [3]. - Revenue is projected to be $30.87 million, down 21.5% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 1.67% lower in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate is lower than the Zacks Consensus Estimate, leading to an Earnings ESP of -1.04%, suggesting a bearish outlook [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict earnings deviation, but its predictive power is significant mainly for positive readings [7][8]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have historically shown a nearly 70% chance of a positive surprise [8]. Historical Performance - In the last reported quarter, Allbirds was expected to post a loss of $3.52 per share but delivered a loss of $3.23, resulting in a surprise of +8.24% [12]. - Over the past four quarters, Allbirds has beaten consensus EPS estimates four times [13]. Conclusion - Allbirds does not appear to be a compelling earnings-beat candidate, and investors should consider other factors when making decisions regarding the stock ahead of the earnings release [16].

Core Viewpoint - Adtalem Global Education (ATGE) is anticipated to report a year-over-year increase in earnings driven by higher revenues in its upcoming earnings report for the quarter ended March 2025, with the actual results being crucial for its near-term stock price movement [1][2]. Earnings Expectations - The consensus estimate for Adtalem's quarterly earnings is $1.63 per share, reflecting an increase of +8.7% year-over-year, while revenues are projected to reach $444.11 million, up 7.6% from the previous year [3]. - The consensus EPS estimate has been revised 1.47% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Adtalem is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +0.20%, which indicates a likelihood of beating the consensus EPS estimate [10][11]. - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [8]. Historical Performance - In the last reported quarter, Adtalem exceeded the expected earnings of $1.39 per share by delivering $1.81, resulting in a surprise of +30.22% [12]. - Over the past four quarters, Adtalem has consistently beaten consensus EPS estimates [13]. Conclusion - Adtalem is positioned as a compelling candidate for an earnings beat, but investors should consider additional factors influencing stock performance beyond just earnings results [16].

Core Viewpoint - The market anticipates that Dave Inc. (DAVE) will report a year-over-year increase in earnings driven by higher revenues in its upcoming earnings report for the quarter ended March 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The consensus estimate for DAVE's quarterly earnings is $1.54 per share, reflecting a year-over-year increase of +148.4%. Revenues are projected to be $91.6 million, which is a 24.5% increase from the same quarter last year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 22.22%, indicating a collective reassessment by analysts regarding the company's earnings prospects [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for DAVE is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -34.85%, suggesting a bearish outlook from analysts [10][11]. Historical Performance - In the last reported quarter, DAVE was expected to post earnings of $1.09 per share but exceeded expectations with earnings of $2.04, achieving a surprise of +87.16%. Over the past four quarters, the company has beaten consensus EPS estimates three times [12][13]. Investment Considerations - Despite a strong Zacks Rank of 1, the negative Earnings ESP reading complicates the prediction of an earnings beat for DAVE. Investors are advised to consider other factors beyond earnings surprises when making investment decisions [11][16].

Core Viewpoint - The market anticipates DraftKings (DKNG) will report a year-over-year increase in earnings and revenues for the quarter ended March 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - DraftKings is expected to post quarterly earnings of $0.18 per share, reflecting a year-over-year increase of +160% [3]. - Revenues are projected to reach $1.42 billion, representing a 21.1% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 24.36% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likelihood of actual earnings deviating from consensus estimates, with positive readings being more predictive of earnings beats [6][7]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have historically produced positive surprises nearly 70% of the time [8]. Historical Performance - DraftKings has only beaten consensus EPS estimates once in the last four quarters, with a notable surprise of -47.37% in the last reported quarter [12][13]. Conclusion - DraftKings does not currently appear to be a strong candidate for an earnings beat, and investors should consider other factors when making decisions regarding the stock ahead of the earnings release [16].